-

Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company’s sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity’s continued evolution and strengthened commitments to creating a lasting, positive impact on the world.

“Whether it’s from developing groundbreaking solutions that drive positive health outcomes or through our sustainability initiatives, such as reducing waste and carbon emissions, we are making substantial strides in creating a healthier, cleaner and more inclusive world for generations to come,“ said Prahlad Singh, president and chief executive officer at Revvity. “The duly named Impact Report represents a purpose-driven shift for Revvity to a holistic, sustainable business approach – one that underlies our approach across the entire company.”

The report shares how the Company is positively impacting the environment and society through its responsible business philosophy and operations. Below are several highlights:

  • Achieved a -7% reduction in Scope 1 and 2 emissions in 2023, ahead of plan towards achieving longer-term goals.
  • Implemented a sustainability due diligence program covering the majority of annual direct material supplier spend.
  • Achieved 75% employee satisfaction in 2023 with 85% employee participation in an employee experience survey.
  • Maintained approximately 40% female representation across leadership positions.
  • Expanded audited gender pay gap collection and analysis to additional countries with further expansion expected over the next 12 months.
  • Introduced new corporate policies covering key emerging topics including ethical artificial intelligence, sustainable procurement, and cyber risk management, amongst others.
  • Created and funded new Revvity Access STEM Scholarships with Northeastern University and University of California San Diego to help support the development of the next generation of scientists.

To learn more about Revvity’s commitments and progress visit esg.revvity.com.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Contacts

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

Media Relations:
Chet Murray
(781) 663-5719
chet.murray@revvity.com

Revvity

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Versions

Contacts

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

Media Relations:
Chet Murray
(781) 663-5719
chet.murray@revvity.com

More News From Revvity

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acce...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global Healthcare Conference Tuesday, December 2, 2025 9:00 a.m. ET – Prahlad Singh, president and chief execu...

Revvity Announces Financial Results for the Third Quarter of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025. The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $82 million, as compared to $98 million for the same period a year ago. GAAP ope...
Back to Newsroom